Phaseline

Companies › TrueBinding

TrueBinding: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Psychiatry; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TB006–Phase 2Parkinson's Disease (PD); Autism Spectrum DisorderNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06773962TB006Phase 2Parkinson's Disease (PD)NeurologyNov 2026
NCT06500637TB006Phase 2Autism Spectrum DisorderPsychiatryDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Reunion Neuroscience Noema Pharma Spinogenix Shanghai Auzone Biological Technology MapLight Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.